|
May 16
|
Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease
|
|
May 14
|
Q1 2024 Voyager Therapeutics Inc Earnings Call
|
|
May 14
|
Voyager Therapeutics Inc (VYGR) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
|
|
May 13
|
Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 13
|
Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
|
|
May 8
|
Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
|
|
May 6
|
Voyager Therapeutics' (NASDAQ:VYGR) three-year earnings growth trails the splendid shareholder returns
|
|
May 6
|
Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast
|
|
May 3
|
Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
|
|
May 2
|
Jazz (JAZZ) Q1 Earnings & Sales Fall Short of Estimates
|
|
Apr 22
|
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
|
|
Apr 16
|
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
|
|
Apr 9
|
Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
|
|
Mar 30
|
Buy Voyager Stock, Analyst Says. The Little Biotech Could Have Big Breakthroughs.
|
|
Mar 26
|
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 13
|
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
|
|
Mar 9
|
12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
|
|
Mar 4
|
Analysts Just Made A Major Revision To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Revenue Forecasts
|
|
Feb 21
|
Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast
|
|
Feb 20
|
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research
|